Abstract
Diluted Russell Viper Venom Time (dRVVT) has become the most popular test to detect Lupus Anticoagulant (LA). dRVVT is more sensitive than other global tests employed to detect LA and is not affected by inhibitors of factor VIII or IX. The test is most successfully implemented if you observe three steps in its execution: screening, mixing, and confirmatory studies. Interference due to the presence of heparin in tested plasma must be excluded by means of thrombin time (TT). The prior use of Vitamin K Antagonists (VKAs) or Non-vitamin K Oral Anticoagulants (NOACs) must also be evaluated by means of International Normalized Ratio, or specific tests, respectively.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Feinstein DI, Rapaport SI (1972) Acquired inhibitors of blood coagulation. Prog Haemost Thromb 1:75–95
Thiagarajan P, Shapiro SS, De Marco L (1980) Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant. J Clin Invest 66:397–405
Pengo V, Balestrieri G, Tincani A, Spatola L et al (1997) Utilization of dilute Russell's viper venom time to detect autoantibodies against beta 2-glycoprotein I which express anticoagulant activity in the presence but not in the absence of exogenous phospholipids. Thromb Haemost 77:123–126
Pengo V, Biasiolo A, Rampazzo P et al (1999) dRVVT is more sensitive than KCT or TTI for detecting lupus anticoagulant activity of anti-b2-Glycoprotein-I autoantibodies. Thromb Haemost 81:256–258
Galli M, Comfurius P, Maassen C et al (1990) Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544–1547
McNeil HP, Simpson RJ, Chesterman CN et al (1990) Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 87:4120–4124
Matsuura E, Igarashi Y, Fujimoto M et al (1990) Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 336:177–178
Galli M, Luciani D, Bertolini G et al (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101:1827–1832
de Laat B, Derksen RH, Urbanus RT et al (2005) IgG antibodies that recognize epitope Gly40-Arg43 in domain I of beta 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105:1540–1545
de Laat B, Pengo V, Pabinger I et al (2009) The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study. J Thromb Haemost 7:1767–1773
Pengo V, Ruffatti A, Tonello M et al (2015a) Antiphospholipid syndrome: antibodies to Domain 1 of β2-glycoprotein 1 correctly classify patients at risk. J Thromb Haemost 13:782–787
Pengo V, Testa S, Martinelli I et al (2015b) Incidence of a first thromboembolic event in carriers of isolated lupus anticoagulant. Thromb Res 135:46–49
Thiagarajan P, Pengo V, Shapiro SS (1986) The use of dilute Russell’s viper venom time for the diagnosis of lupus anticoagulants. Blood 68:869–874
Thiagarajan P, Shapiro SS (1983) Lupus anticoagulants. In: Colman RW (ed) Methods in Hematology: Disorders of thrombin formation other than hemophilia. Livingston, New York
McGlasson DL, Fritsma GA (2013) Comparison of six dilute russell viper venom time lupus anticoagulant screen/confirm assay kits. Semin Thromb Hemost 39:315–319
Pengo V, Tripodi A, Reber G et al (2009) Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 7:1737–1740
Keeling D, Mackie I, Moore GW et al (2012) Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 157:47–58
Moore GW, Savidge GF (2004) Heterogeneity of Russell's viper venom affects the sensitivity of the dilute Russell’s viper venom time to lupus anticoagulants. Blood Coagul Fibrinolysis 15:279–282
Merriman E, Kaplan Z, Butler J et al (2011) Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 105:385–386
Mani H, Hesse C, Stratmann G et al (2013) Ex vivo effects of low-dose rivaroxaban on specific coagulation assays and coagulation factor activities in patients under real life conditions. Thromb Haemost 109:127–136
Tripodi A, Braham S, Moia M (2014) Laboratory tests during direct oral anticoagulant treatment. Intern Emerg Med 9:903–905
Devreese KM, de Laat B (2015) Mixing studies in lupus anticoagulant testing are required at least in some type of samples. J Thromb Haemost 13:1475–1478
Loeliger A (1959) Prothrombin as cofactor of circulating anticoagulant in systemic lupus crythematosus. Thromb Diath Haemorrh 3:237–256
van Os GM, de Laat B, Kamphuisen PW et al (2011) Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time. J Thromb Haemost 9:1657–1659
Arachchillage DR, Mackie IJ, Efthymiou M et al (2015) Interactions between rivaroxaban and antiphospholipid antibodies in thrombotic antiphospholipid syndrome. J Thromb Haemost 13:1264–1273
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Pengo, V., Bison, E., Banzato, A., Zoppellaro, G., Jose, S.P., Denas, G. (2017). Lupus Anticoagulant Testing: Diluted Russell Viper Venom Time (dRVVT). In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_14
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_14
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols